SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-22-000187
Filing Date
2022-01-10
Accepted
2022-01-10 08:24:25
Documents
15
Period of Report
2022-01-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rare-20220110.htm   iXBRL 8-K 54905
2 EX-99.1 rare-ex99_1.htm EX-99.1 51574
3 GRAPHIC img45776771_0.jpg GRAPHIC 14863
4 GRAPHIC img45776771_1.jpg GRAPHIC 14863
  Complete submission text file 0000950170-22-000187.txt   275086

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rare-20220110.xsd EX-101.SCH 2501
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rare-20220110_pre.xml EX-101.PRE 10000
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rare-20220110_lab.xml EX-101.LAB 13562
9 EXTRACTED XBRL INSTANCE DOCUMENT rare-20220110_htm.xml XML 4746
Mailing Address 60 LEVERONI COURT NOVATO CA 94949
Business Address 60 LEVERONI COURT NOVATO CA 94949 415-483-8800
Ultragenyx Pharmaceutical Inc. (Filer) CIK: 0001515673 (see all company filings)

IRS No.: 272546083 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36276 | Film No.: 22519817
SIC: 2834 Pharmaceutical Preparations